Trial Profile

A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavodelpar (Primary)
Indications MELAS syndrome; Mitochondrial myopathies
Focus Registrational; Therapeutic Use
Acronyms STRIDE
Sponsors Reneo Pharmaceuticals

Most Recent Events

18 Oct 2023 Status changed from active, no longer recruiting to completed.
10 Aug 2023 According to a Reneo Pharmaceuticals media release, topline result from this study expected in the fourth quarter this year
15 Jun 2023 According to a Reneo Pharmaceuticals media release, study design will be presented at the 2023 Mitochondrial Medicine Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com